Smoflipid - Fresenius Kabi

Drug Profile

Smoflipid - Fresenius Kabi

Alternative Names: Smoflipid

Latest Information Update: 15 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fresenius Kabi
  • Class Fatty acids; Lipids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Nutrition disorders

Most Recent Events

  • 04 Jan 2017 Biomarkers information updated
  • 18 Aug 2016 Launched for Nutritional disorders (In adults) in USA (IV)
  • 13 Jul 2016 Registered for Nutritional disorders (In adults) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top